Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immunodeficiency Virus (HIV) Status and Type of Vaccine: A Matched Case-Control Observational Study
Matthew A. Spinelli, Michael J. Peluso, Kara L. Lynch, Cassandra Yun, David V. Glidden, Timothy J. Henrich, Steven G. Deeks, Monica Gandhi
Abstract
Following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination, people living with human immunodeficiency virus (HIV, PLWH) had lower surrogate virus neutralization test response (P = .03) and a trend toward lower immunoglobulin G (IgG) response (P = .08), particularly among those with lower CD4+ T-cell counts and who received the BNT162b2 vaccine. Study of the impact of supplemental vaccine doses among PLWH is needed.
Topics & Concepts
MedicineImmunologyVaccinationVirologyAntibodyVirusImmunoglobulin GCoronavirusCoronavirus disease 2019 (COVID-19)Internal medicineDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies